Ziftomenib (KO-539)

About Kura Oncology

Kura Oncology's mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. The company has built a clinical-stage pipeline anchored by a deep scientific understanding of cancer biology, particularly the RAS pathway, and is advancing programs like tipifarnib (FTI), KO-2806 (FTA), and ziftomenib (menin inhibitor) in targeted populations and rational combinations. Its strategy focuses on expanding patient populations and leveraging combination therapies to overcome resistance, aiming to deliver durable remissions in areas of significant unmet need such as HRAS-mutant head and neck squamous cell carcinoma (HNSCC) and NPM1-mutant acute myeloid leukemia (AML).

About Kura Oncology

Kura Oncology's mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. The company has built a clinical-stage pipeline anchored by a deep scientific understanding of cancer biology, particularly the RAS pathway, and is advancing programs like tipifarnib (FTI), KO-2806 (FTA), and ziftomenib (menin inhibitor) in targeted populations and rational combinations. Its strategy focuses on expanding patient populations and leveraging combination therapies to overcome resistance, aiming to deliver durable remissions in areas of significant unmet need such as HRAS-mutant head and neck squamous cell carcinoma (HNSCC) and NPM1-mutant acute myeloid leukemia (AML).

Therapeutic Areas